期刊文献+

声诺维在心内膜缘显像及心肌灌注中的效果评价 被引量:13

The effect of SonoVue in endocardial border delineation and myocardial perfusion
原文传递
导出
摘要 目的 评价外周静脉注射造影剂声诺维对超声心动图心内膜缘显像的增强作用及其在心肌灌注中的效果。方法 分别在基础和非线性成像条件下 ,对 90例患者注射声诺维 ,用二维超声进行观察心内膜缘显像的改善 ,并观察非线性成像条件下心肌灌注情况及不良事件。结果 造影剂在右心腔显影后很快在左心腔显影 ,原来显示欠清的左室心内膜缘得到满意的显影 ,声诺维能很好显示心肌灌注情况 ,无严重不良事件 ,不良事件总发生率为 6 8% ,其中可能由造影剂引起的不良事件发生率 1 1%。结论 声诺维可满意地增强心内膜缘的显影和显示心肌灌注 。 Objective To evaluate the enhancement of endocardial border delineation and displaying of myocardial perfusion by the contrast agent SonoVue intravenously.Methods Under mode of fundamental imaging and nonlinear imaging respectively, 90 patients were injected with SonoVue and observed for improvement of endocardial border delineation by two dimension echo.In the meantime, displaying of myocardial perfusion by SonoVue was also investigated under mode of nonlinear imaging. Adverse events were monitored. Results (1) SonoVue stained the left heart chambers of the patients right away after the right heart chambers had been stained. Endocardial border delinenation of the left heart in 90 patients were all improved by SonoVue. (2)SonoVue can well display myocardial opacification (3) No serious adverse events occurred throughout the study. All nonserious adverse events were minor, mild, and rapidly self-resolving. Total incidence of adverse events was 6.8% and the incidence of adverse events possibly related to SonoVue was 1.1%. Conclusion SonoVue is a safe transpulmonary agent and can satisfactorily improve the endocardial border delineation and show myocardial perfusion.
出处 《中华内科杂志》 CAS CSCD 北大核心 2004年第11期824-827,共4页 Chinese Journal of Internal Medicine
关键词 心内膜 心肌灌注 不良事件 造影剂 发生率 观察 效果评价 情况 结论 目的 Echocardiography Endocardium SonoVue
  • 相关文献

参考文献9

  • 1Schneider M. Related Articles, Links Characteristics of SonoVue trade mark. Echocardiography, 1999 ,16:743-746.
  • 2Becher H,Tiemann S, Kuntz-Hehner S,et al.Diagnostic impact of contrast echocardiography for assessment of left ventricular function and myocardial perfusion in patients with coronary artery disease. Eur Heart J,2002,4(Suppl C):C12-C21.
  • 3Bokor D. Diagnostic efficacy of SonoVue. Am J Cardiol, 2000,86:19G-24G.
  • 4Bauer A, Solbiati L, Weissman N. Ultrasound imaging with SonoVue: low mechanical index real-time imaging.Acad Radiol,2002,9 Suppl 2:S282-S284.
  • 5Masugata H, Lafitte S, Peters B, et al. Comparison of real-time and intermittent triggered myocardial contrast echocardiography for quantification of coronary stenosis severity and transmural perfusion gradient. Circulation, 2001,104:1550-1556.
  • 6Senior R, Kaul S, Soman P, et al. Power doppler harmonic imaging: a feasibility study of a new technique for the assessment of myocardial perfusion. Am Heart J, 2000,139(2 Pt 1):245-251.
  • 7Schneider M. Design of an ultrasound contrast agent for myocardial perfusion. Echocardiography,2000,17(6 Pt 2):S11-S16.
  • 8Bokor D, Chambers JB, Rees PJ, et al. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease. Invest Radiol,2001 ,36:104-109.
  • 9Senior R, Andersson O, Caidahl K, et al. Enhanced left ventricular endocardial border delineation with an intravenous injection of SonoVue, a new echocardiographic contrast agent: a European multicenter study. Echocardiography, 2000,17:705-711.

同被引文献186

引证文献13

二级引证文献125

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部